ROCKVILLE, Md., Nov. 11 Novavax, Inc. (Nasdaq: NVAX) a clinical-stage vaccine company, announced today that John Trizzino, Senior Vice President, International and Government Alliances, will be presenting at the Influenza Congress USA 2009. Mr. Trizzino's presentation will take place at 3:30 pm local time on November 20, 2009 at The Westin Washington, Washington D.C. Mr. Trizzino will be discussing regional partnership drivers, benefits of regional partnerships and value-creation through regional partnerships in a Case Study titled: Regional partners as a unique commercialization strategy.
Advertisement
About the Influenza Congress USA 2009
Influenza Congress USA is an annual influenza conference in North America addressing every aspect of influenza policy and planning, influenza research, development and stakeholder partnerships. The influenza vaccine is the fastest growing segment in the adult vaccine market and the United States accounts for over 50% of the global vaccine market. Annually, more than 3.5 million people die of influenza. By 2016, this market is expected to grow to $4.4 billion. H1N1 remains the most immediate threat.
Advertisement
About Novavax
Novavax, Inc. is a clinical-stage biotechnology company, creating novel vaccines to address a broad range of infectious diseases worldwide, including H1N1, using advanced proprietary virus-like-particle (VLP) technology. The company produces potent VLP -based recombinant vaccines utilizing new and efficient manufacturing approaches. Novavax is committed to using its VLP technology to create country-specific vaccine solutions. The Company has formed a joint venture with Cadila Pharmaceuticals, named CPL Biologicals, to develop and manufacture vaccines, biological therapeutics and diagnostics in India. Additional information about Novavax is available on the company's website: www.novavax.com
SOURCE Novavax, Inc.